# Lantern Pharma

Source: https://onco.cc/companies/lantern-pharma/  
OnCo record `lantern-pharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Lantern Pharma is a Texas company that uses its RADR machine-learning platform to revive shelved cancer drugs; LP-184 is a DNA-damaging agent activated in tumours with DNA repair defects, including glioblastoma.

## Summary

Lantern Pharma applies its RADR artificial-intelligence platform to match small molecules with the tumours and biomarkers most likely to respond. LP-184 is an acylfulvene prodrug activated by the enzyme PTGR1 that causes DNA damage in cells with defective nucleotide excision repair; it is in phase 1 trials in solid tumours and, as LP-184 for glioblastoma, holds orphan and fast track designations. LP-284 targets B-cell lymphomas and LP-300 is in a phase 2 trial in never-smokers with lung adenocarcinoma.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Lantern Pharma Inc.; NASDAQ:LTRN
- Tags: drug-maker
- HQ: Dallas, Texas
- Type: biotech
- Website: https://www.lanternpharma.com/
- Ticker: NASDAQ:LTRN

## Sources

- Official website: https://www.lanternpharma.com/

## Connected records

- drugs: [LP-184](https://onco.cc/drugs/lp-184/)

---
JSON: https://onco.cc/api/v1/entities/lantern-pharma.json